Systemic mononuclear multiple allogenic cord blood cell therapy (Sklifosovsky Institute Of Emergency Care)

N/A

Report date: 2023/01/30 20:00:39

Base Information

Drug NameSystemic mononuclear multiple allogenic cord blood cell therapy (Sklifosovsky Institute Of Emergency Care)

Drug Alias NameMultiple systemic (i.v.) administration of allogenic non-related group- and rhesus-compatible mononuclear cord blood cells(Sklifosovsky Institute Of Emergency Care)

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy > Monocyte cell therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsSpinal Cord Injuries

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryRussian Federation

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesSklifosovsky Institute Of Emergency Care

China Registration ClassN/A

Develop Information

Active CompaniesSklifosovsky Institute Of Emergency Care

Inactive CompaniesN/A

Active IndicationsSpinal Cord Injuries

Inactive IndicationsN/A

Other Information

ATC CodeN/A